<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03235349</url>
  </required_header>
  <id_info>
    <org_study_id>M15-593</org_study_id>
    <nct_id>NCT03235349</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment- Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection</brief_title>
  <official_title>An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Na誰ve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, single-arm, open-label, multicenter study to evaluate the efficacy and
      safety of ABT-493/ABT-530 in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected
      Asian participants with compensated cirrhosis with or without Human Immunodeficiency Virus
      (HIV) co-infection who are HCV treatment-na誰ve or treatment-experienced with interferon (IFN)
      (alpha, beta or pegylated interferon [pegIFN]) with or without ribavirin (RBV) OR sofosbuvir
      with RBV with or without IFN.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Anticipated">March 8, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [&lt;LLOQ]) 12 weeks after the last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Virologic Failure</measure>
    <time_frame>Up to 12-16 weeks while on treatment</time_frame>
    <description>On-treatment virologic failure was defined as confirmed increase of &gt; 1 log10 IU/mL above the lowest value post-baseline HCV RNA during treatment; confirmed HCV RNA &gt;= 100 IU/mL after HCV RNA &lt; LLOQ during treatment, or with quantifiable HCV RNA at end of treatment with at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-treatment Relapse</measure>
    <time_frame>From the end of treatment through 12 weeks after the last dose of study drug</time_frame>
    <description>Post-treatment relapse was defined as confirmed HCV RNA &gt;= LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels &lt; LLOQ at the end of treatment excluding reinfection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HCV/HIV Co-infected Participants Achieving SVR12</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>SVR12 was defined as plasma HCV RNA level less than LLOQ 12 weeks after the last dose of study drug.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>ABT-493/ABT-530</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 or 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-493/ABT-530</intervention_name>
    <description>Tablet; ABT-493 coformulated with ABT-530</description>
    <arm_group_label>ABT-493/ABT-530</arm_group_label>
    <other_name>ABT-493 also known as glecaprevir ABT-530 also known as pibrentasvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be of Asian descent.

          -  Screening laboratory result indicating Hepatitis C Virus (HCV) Genotype (GT) 1, 2, 3,
             4, 5 or 6 infection.

          -  Positive anti-HCV antibody (Ab) and HCV Ribonucleic acid (RNA) greater than or equal
             to 1000 IU/ mL at Screening Visit.

          -  Chronic HCV infection defined as one of the following:

          -  Positive for anti-HCV Ab or HCV RNA at least 6 months before Screening; or

          -  A liver biopsy consistent with chronic HCV infection; or

          -  HCV treatment-na誰ve to any approved or investigational HCV treatment or
             treatment-experienced with interferon (IFN) (alpha, beta or pegylated
             interferon[pegIFN] with or without ribavirin (RBV) OR sofosbuvir with RBV with or
             without IFN. Previous treatment must have been completed &gt;= 8 weeks prior to
             screening.

          -  Participants must have documented cirrhosis as defined in the protocol.

          -  Absence of hepatocellular carcinoma (HCC) as defined in the protocol.

          -  Participants enrolled with human immunodeficiency virus (HIV)-1 and HCV co-infection
             must also meet the following criteria:

          -  Positive test result for Human Immunodeficiency Virus antibody (HIV Ab) at Screening.

          -  Na誰ve to treatment with any antiretroviral therapy (ART) with a CD4+ count greater
             than or equal to 500 cells/mm3 (or CD4+ % &gt;= 29%)

          -  On a stable, qualifying HIV-1 ART regimen with CD4+ count &gt;= 200 cells/mm3 (or CD4+ %
             &gt;= 14%) at Screening; and plasma HIV-1 RNA below lower limit of quantification (LLOQ)
             by an approved plasma HIV-1 RNA quantitative assay at Screening and at least once
             during the 12 months prior to Screening.

        Exclusion Criteria:

          -  Positive test result for Hepatitis B surface antigen (HbsAg) or positive test result
             for hepatitis B virus (HBV) deoxyribonucleic acid (DNA) if HBsAg is negative.

          -  Any cause of liver disease other than chronic HCV-infection.

          -  HCV genotype performed during screening indicating co-infection with more than one HCV
             genotype

          -  Clinically significant abnormalities, other than HCV infection or HCV/HIV co-infection

          -  Chronic human immunodeficiency virus, type 2 (HIV-2) infection

        Additional Exclusion Criteria for participants with HCV/HIV Co-Infection:

          -  For participants on stable ART, taking anti-retroviral agent(s) other than those
             permitted

          -  Treatment for an AIDS-associated opportunistic infection within 12 months of Screening
             or prophylaxis for an AIDS-associated opportunistic infection within 6 months of
             screening

          -  Diagnosis of any clinical AIDS-defining event within 12 months prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Hosp of Jilin Univ</name>
      <address>
        <city>Changchun</city>
        <state>Anhui</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hosp Southern Med Univ</name>
      <address>
        <city>Guangzhou</city>
        <state>Anhui</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University Peoples Hospit</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hosp</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>3rd Affiliated Hosp Sun Yatsen</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1st Aff Hosp Nanchang Univ</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Cli Ctr</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Di Tan Hosp Cap Med</name>
      <address>
        <city>Beijing</city>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Youan Hosp, Cap Med Un</name>
      <address>
        <city>Beijing</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>2nd Affiliated Hosp Chongqing</name>
      <address>
        <city>Chongqing</city>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mengchao Hepatobiliary Hospita</name>
      <address>
        <city>Fuzhou</city>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou, Hainan</city>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China PLA 81 Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shengjing Hosp China Med Univ</name>
      <address>
        <city>Shenyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>6th People's Hosp Shenyang</name>
      <address>
        <city>Shenyang</city>
        <zip>110006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1st Aff Hosp Xinjiang Med Uni</name>
      <address>
        <city>Urumqi</city>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fourth Military Medical Univ.</name>
      <address>
        <city>Xi'an</city>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1st Aff Hos Xi'an Jiaotong Uni</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Peoples Hosp</name>
      <address>
        <city>Zhengzhou, Henan</city>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hosp</name>
      <address>
        <city>Busan</city>
        <state>Busan Gwang Yeogsi</state>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National Univ Bundang ho</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggido</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan Nat Univ Yangsan Hosp</name>
      <address>
        <city>Yangsan-si,</city>
        <state>Gyeongsangnamdo</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Incheon Gwang Yeogsi</state>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje Univ Busan Paik Hosp</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>July 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C Virus (HCV)</keyword>
  <keyword>Genotype 1 to 6</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Compensated Cirrhosis</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>co-infection</keyword>
  <keyword>Treatment-na誰ve</keyword>
  <keyword>treatment-experienced</keyword>
  <keyword>interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

